Aldon

Quick links to important sections

Aldon

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Aldon

Property Description
Active Ingredient Ondansetron (INN)
Form Tablets, Oral Solution, Solution for Injection
Pharmacological Class Antiemetic (Selective 5-HT3 Receptor Antagonist)
Common Use Prevention and relief of severe nausea and vomiting
Origin Synthetic compound

What Type of Medicine is Aldon and What is it Made Of?

Aldon is a specialized, single-ingredient medicinal product containing the active pharmaceutical ingredient Ondansetron (INN). The drug is classified within the pharmacological category of antiemetics, which are medicines used to counter vomiting and nausea. More specifically, Ondansetron functions as a Selective 5-HT3 Receptor Antagonist, reflecting its precise and targeted action on a specific chemical pathway. This class of medicine is clinically recognized for its powerful effect on acute nausea. Ondansetron is a synthetic compound, meaning it is chemically synthesized rather than being derived from natural sources. Its composition relies on the active substance combined with standard pharmaceutical excipients—such as binders for solid forms or a sterile aqueous vehicle for injections—required to create a stable and administrable medicine.

Available Forms and General Purpose of Aldon (Ondansetron)

The general purpose of Aldon is to relieve or prevent severe nausea and vomiting by inhibiting the body's emetic reflex. This medicine is often designated as a prescription-only medicine (Rx) due to the potent nature of its mechanism. The medicine is manufactured in various dosage forms to accommodate different administration requirements, including tablets for oral intake, as well as a sterile solution for injection intended for parenteral administration. This variety ensures the active substance can be delivered even in critical situations. By selectively blocking the 5-HT3 receptors, Aldon effectively interrupts the signals traveling from the gastrointestinal system and the brain that trigger the sensation of sickness, providing a powerful, targeted benefit against acute emesis.

What side effects are possible with Aldon?

Possible Side Effects and Safety Information

The safety profile of Aldon (Ondansetron) is established through regulatory classifications that organize possible effects by the physiological system affected and their reported frequency in clinical trials and post-marketing surveillance. This approach ensures all documented safety concerns, from common occurrences to serious adverse reactions, are clearly communicated according to government health authority standards.

Adverse Reaction Categories

Adverse reactions are formally categorized by frequency in official documents:

  • Very Common (ge 1/10): Headache.
  • Common (ge 1/100 to < 1/10): Constipation, fatigue, and a temporary feeling of warmth or flushing.
  • Uncommon (ge 1/1,000 to < 1/100): Seizures, movement disorders (extrapyramidal reactions), and transient elevations in liver function tests.
  • Rare (ge 1/10,000 to < 1/1,000): Transient visual disturbances, including blurred vision.

Serious Adverse Reactions and Safety Limitations

Official labeling documents specific, serious safety concerns. The medicine is associated with a risk of QT Interval Prolongation, which can lead to a potentially fatal abnormal heart rhythm known as Torsade de Pointes. Consequently, use is generally avoided in individuals with congenital long QT syndrome. The product is also noted in regulatory documents to potentially cause Serotonin Syndrome, particularly when combined with other serotonergic medicines.

Safety considerations apply to certain populations, including those with severe hepatic impairment, where drug clearance is reduced, and total daily exposure is limited as noted in the label. Orally disintegrating forms contain phenylalanine, a factor noted for individuals with Phenylketonuria. The medicine may also mask signs of a progressive bowel obstruction (ileus) or gastric distension in some patients, a factor included in regulatory warnings.

Overdose and Emergency Response

Overdose with Aldon has been documented to present with several specific clinical manifestations. These documented signs include transient blindness or sudden loss of vision, typically resolving spontaneously within a short duration. Other reported manifestations include severe constipation, hypotension (low blood pressure), and episodes of fainting or feeling light-headed.

Regulators emphasize the risk of severe and life-threatening outcomes associated with overdose. These center on the cardiovascular system, involving dose-dependent QT interval prolongation and postmarketing reports of Torsade de Pointes (a potentially fatal abnormal heart rhythm). Furthermore, Serotonin Syndrome has been documented following overdose of the drug alone, with some reported cases having a fatal outcome. In children, Serotonin Syndrome has been specifically reported after accidental overdose.

Immediate medical attention is required upon any suspicion of overdose or if symptoms of a severe reaction occur. Seek urgent medical help for signs such as an irregular heartbeat, shortness of breath, dizziness, or fainting.

Management is defined as symptomatic and supportive therapy, as no specific antidote is known. Due to the cardiac risks, ECG monitoring is recommended. For patients with severe hepatic impairment, regulatory documents specify that the total daily dose should not exceed 8 mg to avoid the potential for increased toxicity.

Therapeutic Uses of Aldon

What Aldon Treats: Main Uses and Benefits

Aldon (Ondansetron) is an antiemetic medicine relevant for the prevention and symptomatic relief of acute, severe nausea and vomiting. Its primary therapeutic benefit is to provide targeted symptomatic support, which contributes to patient comfort and supports stability during periods of intense physiological stress. Its main uses are commonly applied in contexts involving sickness associated with specific medical interventions.


The medication is generally used to address highly acute and intense emetic risk across several key clinical scenarios: specifically, in managing sickness associated with chemotherapy (CINV), radiation therapy (RINV), and during postoperative recovery (PONV). It is also commonly used in situations involving recurrent or persistent severe refractory emetic syndromes.

“Its role is to help ease the overall symptom burden and assist patients in coping more steadily with difficult episodes.”

Controlling Sickness in Specialized Contexts

This medicine is generally applied in settings marked by temporary physiological imbalance, where symptoms become more disruptive during flare-ups or episodes of sudden symptom escalation. By proactively preventing and assisting with the management of severe episodes, Aldon supports the patient during periods of acute sickness and assists with managing symptoms that interfere with comfort during emergence from anesthesia.


Quick Fact: Relief for Severe Nausea
Aldon is commonly used to help with symptoms related to heightened physiological activity and conditions characterized by periods of heightened symptoms, offering supportive relief when symptoms become temporarily overwhelming.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Aldon (Ondansetron) eligibility is defined by strict regulatory criteria concerning patient status and age. The medicine is formally contraindicated in patients with a known hypersensitivity to the drug or any component. Use is also strictly prohibited in patients who are concurrently receiving apomorphine due to the risk of profound hypotension. Furthermore, regulatory documents state that use must be avoided in patients diagnosed with congenital Long QT syndrome due to cardiac risk.

Eligibility is restricted for patients with severe hepatic impairment, for whom the total daily dose must not exceed 8 mg. Conversely, no adjustment in dose is necessary for patients with any degree of renal impairment. Age-related eligibility is established for adults and adolescents. For pediatric patients, the minimum age for use is 6 months for chemotherapy-induced nausea and vomiting (CINV) and 1 month for postoperative nausea and vomiting (PONV) via injection. Safety and efficacy are not established for oral use in children under 4 years for CINV. Use during pregnancy is generally advised only if the benefit justifies the potential risk, as the safety status is not fully established.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Aldon (Ondansetron) exhibits documented interaction patterns that are classified based on pharmacokinetic clearance, pharmacodynamic effects, and formal prohibitions stated in regulatory documents.


Official Interaction Restrictions

Co-administration with Apomorphine is formally contraindicated due to the reported risk of profound hypotension and loss of consciousness. Use is also officially avoided in patients with Congenital Long QT Syndrome.


Documented Interaction Patterns

Type of Interaction Interacting Substances/Condition Documented Outcome
Pharmacokinetic (Clearance) Phenytoin, Carbamazepine, Rifampin (CYP3A4 Inducers) Increased clearance of Aldon, resulting in decreased plasma concentrations (reduced exposure).
Pharmacodynamic (Serotonergic) Serotonergic medicines (e.g., SSRIs, SNRIs) Increased risk of Serotonin Syndrome (additive central nervous system effect).
Pharmacodynamic (Cardiac) Other QT-prolonging medicinal products Increased risk of QT interval prolongation and Torsade de Pointes.
Population-Specific PK Severe Hepatic Impairment Reduced clearance and prolonged half-life of Aldon is documented.

These patterns define a structure that informs necessary restrictions and cautions regarding concomitant use, ensuring the interaction profile is strictly aligned with governmental regulatory labeling.

Mechanism of Action

Dual-Site Blockade of 5- HT3 Signaling

The action of Aldon (Ondansetron) is based on a highly specific selective antagonism of the serotonin 5- HT3 receptor. This mechanism is exerted on both peripheral nerve endings in the gut's lining (vagal afferents) and within the brain's Chemoreceptor Trigger Zone (CTZ). By blocking these receptor sites, the drug prevents the activation of the ion channel by serotonin (5- HT) released from Enterochromaffin (EC) cells in response to specific stimuli. This antagonism halts the signal transmission to the brain's Vomiting Center, thereby interrupting the signaling within the emetic reflex arc.

Modulation of 5- HT3-Regulated Physiological Processes

The molecular blockade also extends to physiological processes that rely on 5- HT3 signaling in the digestive tract. While primarily targeting nerve transmission, the mechanism influences regulatory processes governing smooth muscle activity. This engagement with the enteric nervous system results in a slowing of colonic transit time, which is a direct physiological consequence of interfering with this specific serotonin pathway.

Dosage and Administration Information

Aldon (Ondansetron) is used according to specific administration protocols. The medicine is authorized for delivery by Oral routes, including tablets, solution, and orally disintegrating tablets (ODTs), as well as by Intravenous (IV) and Intramuscular (IM) injection.

Usage is characterized by prophylactic timing, requiring the initial dose to be administered approximately 30 minutes prior to the start of emetogenic therapy. Subsequent doses for continued control are typically scheduled every 12 hours for a total duration of one to two days after the primary treatment has concluded.

Dosing varies based on the type of therapy. For highly emetogenic chemotherapy, the standard adult approach involves either a single 24 mg oral dose or three IV doses of 0.15 mg/kg, with no single IV dose to exceed 16 mg. The IV solution requires dilution in a compatible fluid and must be infused over 15 minutes for the proper administration of the active substance. The oral tablets may be taken with or without food.

A mandatory administration rule addresses patient context: the total daily dose must not exceed 8 mg in patients with severe hepatic impairment. The single 32 mg IV dose is no longer supported.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Aldon (Ondansetron)


Aldon was studied for its use in research exploring how symptoms change over time related to cancer treatment. Researchers primarily used Randomized Controlled Trials (RCTs), alongside numerous comprehensive Systematic Reviews and Meta-analyses. These studies research examined outcomes related to outcomes describing episodic or acute changes, specifically tracking the complete absence of vomiting and the frequency of rescue antiemetic use.

The use of Aldon was studied for its potential in research exploring short-term symptom changes after an operation using a substantial number of short-term, placebo-controlled and comparative RCTs. Studies monitored the incidence of emesis (vomiting or retching) and patient-reported outcomes describing perceived discomfort during the recovery phase, as well as the frequency of rescue medication use.

Research explored short-term symptom changes associated with radiotherapy, particularly when it targets high-risk, emetogenic body areas. These trials research describes the outcomes related to systemic or functional imbalance, which include tracking the goal of complete symptom absence, across the entire radiation course.

The core of the clinical evidence for Aldon is derived from trials focused on research exploring short-term symptom patterns. In the case of chemotherapy and surgical sickness, the follow-up durations were limited. While research highlights changes measured during the study period for acute episodes, long-term effects are not fully established regarding the durability of these patterns. For certain subgroups, such as older adults with multiple comorbidities, the data for certain groups remain insufficient. The results apply only to the populations studied, and researchers must often rely on subgroup analyses for patients with specific health characteristics.

Key Studies & References

  1. The preventive effects of ondansetron on chemotherapy-induced nausea and vomiting in adult cancer patients: systematic review from ClinicalTrials.gov
  2. GUIDELINE FOR THE MANAGEMENT OF CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING (NHS England)
  3. Ondansetron - StatPearls (General Clinical Overview)

Frequently Asked Questions (FAQ)

Common questions about Aldon (FAQ)

Q: Is Aldon a long-term or short-term medication?

Official prescribing information details that Aldon is generally intended for acute, short-term use. This usage pattern is for acute, short-term periods, such as those related to chemotherapy, radiation, or surgery, for the prevention of nausea and vomiting.

Q: Are there any specific foods or drinks to avoid while using Aldon?

Regulatory precautions state that the orally disintegrating tablet (ODT) form of Aldon contains phenylalanine. This information is important for patients who have been diagnosed with Phenylketonuria (PKU).

Q: How quickly should I expect to feel the effects of Aldon?

Official pharmacokinetic data indicates that the highest concentration of the medicine in the blood is typically reached about 1.5 hours after taking an oral dose. This is the time point used for measuring how quickly the drug is absorbed.

Q: How long does the main effect of one dose of Aldon usually last?

Regulatory data shows that the mean half-life of Aldon in adults is generally between 3.5 and 5.7 hours. The half-life refers to the time it takes for half of the drug to be eliminated from the body.

Q: How long does it take for Aldon to be fully cleared from the body?

Based on official pharmacokinetic data, the mean elimination half-life ( Tfrac12) in adults is approximately 3.5 to 5.7 hours. This half-life value is used to estimate the drug's clearance time from the body.

Q: Is Aldon appropriate for use by patients over the age of 65?

Regulatory documents indicate that no dosage adjustment is typically needed for patients over 65 years of age. Studies have shown that the effectiveness and tolerability of the drug were similar to that observed in younger adults.

Q: How is Aldon different from other drugs used for the same condition?

Aldon is classified as a selective 5-HT3 receptor antagonist. This means its mechanism of action is highly specific, focused on blocking the action of a specific chemical (serotonin) on certain nerve receptors involved in triggering nausea and vomiting.

Q: What is the risk of overdose described in the official documents?

Official documents on overdose risk describe symptoms such as temporary vision loss, severe constipation, fainting due to low blood pressure, and a potential for an irregular heart rhythm. Warnings are included in the product information.

Q: What is the main finding regarding Aldon in published clinical trials?

The main finding from clinical trial data supports the drug's use for preventing nausea and vomiting. This includes symptoms associated with chemotherapy, radiation, and surgery, which are the drug's official indications for use.

Q: Does Aldon require any special monitoring or lab tests?

Regulatory documents note that asymptomatic increases in liver function tests (LFTs) have been reported in some patients. Official warnings note that monitoring for signs of Serotonin Syndrome is a consideration when the drug is taken with other serotonergic medicines.

Q: Are there any generic versions of Aldon available?

Yes, the active ingredient in Aldon, which is called Ondansetron, is available in generic form.

Q: Can Aldon affect my sleep schedule or cause insomnia?

According to the official list of adverse reactions, trouble sleeping or insomnia is a possible side effect of Aldon.

Q: Is it common to experience dizziness while taking Aldon?

Yes, official regulatory documents list dizziness as a commonly reported adverse reaction to Aldon.

Q: Does Aldon cause any changes in mood or behavior?

Official warnings state that changes in mental status, such as agitation, hallucinations, and delirium, are listed as symptoms of Serotonin Syndrome. Serotonin Syndrome is a serious condition that can be associated with the use of Aldon.

Q: Can Aldon be taken with alcohol?

No formal drug interaction with alcohol is noted in the official documentation. However, official documentation suggests that combining the drug with alcohol may increase the occurrence of side effects such as headache or fatigue.

Q: Does Aldon interact with herbal or vitamin supplements?

The regulatory label cautions about potential interactions with serotonergic supplements, as they may increase the risk of Serotonin Syndrome when combined with the drug. This warning applies to supplements that increase serotonin levels.

Q: Can Aldon be used while breastfeeding?

The official label notes that the factors to consider when using the drug while nursing include balancing the benefits of breastfeeding with the mother's clinical need and any potential adverse effects on the infant.

Q: Is Aldon a controlled substance?

No, the active ingredient in Aldon, Ondansetron, is not listed as a scheduled controlled substance according to regulatory agencies.

Q: What are the signs of an allergic reaction to Aldon?

Official product information describes signs of an allergic reaction as potentially including rash, hives (urticaria), and swelling.

Q: Does Aldon cause any issues with driving or operating machinery?

Official labeling contains a caution regarding driving or operating machinery until the patient knows how the medication affects them. This warning is included because Aldon may cause dizziness.

Q: How does Aldon affect blood pressure?

The medicine is contraindicated (prohibited) for use with apomorphine due to the risk of profound low blood pressure (hypotension). Additionally, low or labile blood pressure is mentioned as a possible symptom of Serotonin Syndrome.

Q: What is the half-life of Aldon according to pharmacokinetics data?

According to official pharmacokinetic data, the mean elimination half-life ( Tfrac12) in adults is approximately 3.5 to 5.7 hours. This figure helps define the body's rate of clearing the drug.

Q: Are there any non-serious skin reactions associated with Aldon use?

Yes, the official list of adverse reactions includes non-serious skin reactions such as rash and hives (urticaria).

How should Aldon be stored and disposed of?

How to Store and Dispose of Aldon?

The official storage and disposal requirements for Aldon are based on regulatory standards that ensure product quality and safety.

Storage and Handling Requirement Official Regulatory Statement
Temperature and Environment Store in the original package. Store below a maximum specified temperature (e.g., 25 C or 30 C), and do not freeze.
Protection and Integrity Protect from light and moisture (if applicable per stability data). The container must be kept tightly closed (if applicable).
Child Safety Keep out of the sight and reach of children.
Disposal Return any unused or expired product to the pharmacist or utilize a government-approved drug take-back program. Disposal must comply with local/national regulations for pharmaceutical waste.

These mandated conditions define how the medicine must be protected from environmental factors that could compromise its stability, such as temperature extremes or light exposure. Following the official disposal pathway is required to prevent misuse and environmental contamination.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Aldon found in:

A-Z Index: